---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-025179"
form_type: "8-K"
ticker: "OMER"
cik: "0001285819"
company_name: "OMEROS CORP"
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:38:19.121041+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Omeros Q2 net loss $56M ($0.97/sh) vs $37M; restructures debt with $67M term loan

## Summary
- Net loss $56.0M ($0.97/sh) vs $37.3M ($0.59); includes $17.6M narsoplimab charge, $21.2M debt repurchase.
- Entered $67.1M secured term loan with Athyrium/Highbridge; repurchased $118.1M of 5.25% 2026 notes at ~25% discount.
- Cash and investments $158.9M at June 30; OMIDRIA royalties $10.9M on Rayner net sales $36.4M.
- FDA meeting scheduled for narsoplimab BLA resubmission in TA-TMA; Phase 3 for zaltenibart in PNH on track for late 2024.
- Zaltenibart Phase 2 data: mean hemoglobin improvement 3.27 g/dL; 10/12 patients advanced to monotherapy.

## SEC filing metadata
- accession: 0001437749-24-025179
- form_type: 8-K
- ticker: OMER
- cik: 0001285819
- company_name: OMEROS CORP
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1285819/000143774924025179/0001437749-24-025179-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1285819/000143774924025179/omer20240523_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-025179
- JSON: https://secwatch.observer/filing/0001437749-24-025179.json
- Plain text: https://secwatch.observer/filing/0001437749-24-025179.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.